Vaxcyte, Inc.
US ˙ NasdaqGS ˙ US92243G1085

SecurityPCVX / Vaxcyte, Inc.
InstitutionDriehaus Capital Management Llc
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Driehaus Capital Management Llc closes position in PCVX / Vaxcyte, Inc.

On November 14, 2025 - Driehaus Capital Management Llc filed a 13F-HR form disclosing ownership of 0 shares of Vaxcyte, Inc. (US:PCVX) valued at $0 USD as of September 30, 2025. The entity filed a previous 13F-HR on August 14, 2025 disclosing 73,376 shares of Vaxcyte, Inc.. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-11-14 2025-09-30 13F VAXCYTE COM 92243G108 0 -100.00 0
2025-08-14 2025-06-30 13F VAXCYTE COM 92243G108 73,376 -987,487 -93.08 2,385 -94.05 0.0191
2025-05-15 2025-03-31 13F VAXCYTE COM 92243G108 1,060,863 -105,970 -9.08 40,058 -58.06 0.3861
2025-02-14 2024-12-31 13F VAXCYTE COM 92243G108 1,166,833 -554,463 -32.21 95,517 -51.44 0.7883
2024-11-14 2024-09-30 13F VAXCYTE COM 92243G108 1,721,296 -213,451 -11.03 196,692 34.64 1.6886
2024-08-15 2024-06-30 13F/A-1 VAXCYTE COM 92243G108 1,934,747 66,940 3.58 146,093 14.50 1.4133
2024-08-14 2024-06-30 13F VAXCYTE COM 92243G108 1,934,747 66,940 146,093 1.4085
2024-05-15 2024-03-31 13F VAXCYTE COM 92243G108 1,867,807 193,439 11.55 127,590 21.34 1.2711
2024-02-14 2023-12-31 13F VAXCYTE COM 92243G108 1,674,368 350,484 26.47 105,150 55.80 1.2668
2023-11-14 2023-09-30 13F VAXCYTE COM 92243G108 1,323,884 134,027 11.26 67,492 13.58 0.8774
2023-08-14 2023-06-30 13F VAXCYTE COM 92243G108 1,189,857 575,951 93.82 59,421 158.25 0.7502
2023-05-15 2023-03-31 13F VAXCYTE COM 92243G108 613,906 -216,889 -26.11 23,009 -42.24 0.3229
2023-02-14 2022-12-31 13F VAXCYTE COM 92243G108 830,795 247,189 42.36 39,837 184.40 0.5939
2022-11-14 2022-09-30 13F VAXCYTE COM 92243G108 583,606 35,416 6.46 14,007 17.42 0.2121
2022-08-15 2022-06-30 13F VAXCYTE COM 92243G108 548,190 458,190 509.10 11,929 448.71 0.1932
2022-05-16 2022-03-31 13F VAXCYTE COM 92243G108 90,000 90,000 2,174 0.0267
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.